Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PROCEPT BioRobotics (PRCT) Accumulated Expenses (2020 - 2026)

PROCEPT BioRobotics has reported Accumulated Expenses over the past 7 years, most recently at $18.5 million for Q1 2026.

  • Quarterly Accumulated Expenses rose 23.37% to $18.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $18.5 million through Mar 2026, up 23.37% year-over-year, with the annual reading at $23.2 million for FY2025, 7.61% up from the prior year.
  • Accumulated Expenses was $18.5 million for Q1 2026 at PROCEPT BioRobotics, down from $23.2 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $23.2 million in Q4 2025 and troughed at $4.6 million in Q1 2022.
  • The 5-year median for Accumulated Expenses is $14.9 million (2024), against an average of $14.4 million.
  • Year-over-year, Accumulated Expenses surged 110.95% in 2022 and then grew 7.61% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $13.4 million in 2022, then grew by 25.57% to $16.9 million in 2023, then grew by 27.55% to $21.5 million in 2024, then grew by 7.61% to $23.2 million in 2025, then decreased by 20.28% to $18.5 million in 2026.
  • Per Business Quant, the three most recent readings for PRCT's Accumulated Expenses are $18.5 million (Q1 2026), $23.2 million (Q4 2025), and $21.8 million (Q3 2025).